# MoonRISe-1 (NCT06319820)

> A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06319820
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Non-Muscle Invasive Bladder Neoplasms
- Interventions: TAR-210; Gemcitabine; MMC
- Enrollment: 641
- Primary outcome: Disease Free Survival (DFS)

## Commentary we found

- YouTube: 16
- Podcasts: 11
- X threads: 10

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=moonrise-1-nct06319820

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06319820", "email": "<work email>"}; the inbox owner confirms by the emailed link.